Compare Consolidated Edison, Inc. (ED) vs Eli Lilly And Co (LLY) Price & Performance

Consolidated Edison, Inc.Trade

Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

Consolidated Edison, Inc. vs Eli Lilly And Co — how do they compare? Consolidated Edison, Inc. trades at $111.71 (market cap $40.65B), while Eli Lilly And Co trades at $1,180.71 (market cap $1.03T). The key difference: Eli Lilly And Co is far larger — about 25.3× Consolidated Edison, Inc.'s market cap, and Consolidated Edison, Inc. pays the higher dividend (3.15%). Which is the better fit depends on your goals.

	ED	LLY
Market Cap	$40.65B	$1.03T
Sector	Utilities	Health
52-Week High	$115.46	$1.24K
52-Week Low	$95.37	$625.65
Enterprise Value	$67.68B	$1.07T
Dividend Yield	3.15%	0.6%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Consolidated Edison, Inc.

Con Edison (ED) trades at $111.94, showing modest daily gains. The stock exhibits a bullish technical trend with strong moving average signals, while recent earnings have been mixed with a Q1 2026 miss. Revenue growth is steady, supported by a 12.52% net income margin and a reasonable P/E of 18.6. Recent news highlights grid upgrades and electric fleet expansions, aligning with rising power demand trends.

ED offers stable income with a solid dividend history but faces risks from high debt levels and capital expenditure demands. Analyst consensus is cautious, with a hold-heavy rating and a price target below the current price, suggesting limited near-term upside amid macroeconomic and regulatory pressures.

Eli Lilly And Co

LLY trades at $1,154.27, down 2.6% today, amid a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q1 2026 EPS of $8.55 surpassing the $6.97 forecast. Revenue surged to $65.18B in 2025, driving a net income margin of 34.99%. Recent news includes the acquisition of AtaiBeckley for $2.8 billion, expanding its neuroscience pipeline.

Outlook remains positive with a consensus price target of $1,380, though high valuation multiples (P/E 41.09) and competitive pressures in obesity drugs present risks. Analyst sentiment is strongly bullish (73% buy ratings), supporting further upside if execution continues.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

Con Edison to release Q2 2026 earnings on August 6 after market closePRNewsWire · 23 hours agoNeutral View details →

LLY

Lilly to acquire AtaiBeckley for up to $3.8B, boosting its mental health drug pipelineProactive Investors · 7 hours agoBullish Eli Lilly to buy psychedelic drugmaker AtaiBeckley for $2.8B to boost mental health drug pipelineCNBC · 9 hours agoBullish Eli Lilly stock could grow 76% in 3 years driven by blockbuster drugs and new sales channels.Forbes · 2 days agoBullish View details →

About Consolidated Edison, Inc.

Con Ed is a holding company for Consolidated Edison of New York, or CECONY, and Orange & Rockland, or O&R. These utilities provide steam, natural gas, and electricity to customers in southeastern New York—including New York City—and small parts of New Jersey. The two utilities will generate nearly all of Con Ed's earnings once it closes the sale of its clean energy business to RWE. Con Ed's clean energy business owns the second-largest portfolio of utility-scale solar projects in the U.S. Following the sale, Con Ed's only non-utility earnings will come from investments in gas and electric transmission.